Curis, Inc. , a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small ...

Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL management still falls short. What does it actually cost—in dollars, in ...

The last time I spoke about Nurix Therapeutics, Inc. (NRIX), it was with a Seeking Alpha article entitled "Nurix: 'Strong Buy' Bexobrutideg Development And Dual Degrader Zelebrudomide." With respect ...

The rapid development of novel agents and combinations in chronic lymphocytic leukemia/small lymphocytic lymphoma has led to multiple options for frontline therapy and relapse, including continuous ...

ST. JOHNS COUNTY, Fla. — RSVP of St. Johns County is seeking community members to assist with the St. Johns County School District’s summer reading program, with volunteers needed just once a week.

"We anticipate providing updated emavusertib clinical data" from the PCNSL TakeAim Lymphoma combination study "in the first half of 2027" and said Curis is aiming for accelerated submissions in the ...

A simple brain-training program that sharpens how quickly older adults process visual information may have a surprisingly powerful long-term payoff. In a major 20-year study of adults 65 and older, ...

Marriotts Ridge senior Abbi Livay walked past the symbolic finish line each time she entered the clinic for treatment at Johns Hopkins Hospital. Diagnosed with B-Cell acute lymphoblastic leukemia on ...

CLEVELAND, Ohio – Cleveland Hopkins International Airport will host its second “Flight School” event next month, designed to ease anxiety for nervous flyers. The event will run 9 a.m. to 11 a.m.

A Maryland doctor who spent his life helping others spent his 33rd birthday in a hospital bed after receiving a life-altering diagnosis. Tim Kaniecki, a University of Pittsburgh graduate who later ...